Ginkgo Bioworks Holdings, Inc. vs. Halozyme Therapeutics, Inc.
Halozyme Therapeutics, Inc. (HALO) comes out ahead, leading on 7 of 8 compared factors.
Size & Scale
| DNA | HALO | |
|---|---|---|
| Market Cap | $863.98 million | $12.47 billion |
| Revenue (TTM) | $111.86 million | $1.66 billion |
| Net Income (TTM) | $-290,803,000 | $413.60 million |
HALO leads on 3 of 3 size & scale factors.
Valuation
| DNA | HALO | |
|---|---|---|
| P/E Ratio | — | 31.85 |
| Price / Book | 2.06 | 86.87 |
| Price / Sales | 7.72 | 7.49 |
DNA and HALO split the valuation factors evenly.
Profitability
| DNA | HALO | |
|---|---|---|
| Net Margin | -259.96% | 24.86% |
| Return on Equity | -69.19% | 288.13% |
HALO leads on 2 of 2 profitability factors.
Risk & Sentiment
| DNA | HALO | |
|---|---|---|
| Short Interest | 18.73% | 9.79% |
HALO leads on 1 of 1 risk & sentiment factors.
Dig deeper: DNA overview, DNA financials, HALO overview, HALO financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.